S2686
RTT - Patient experience and quality of life
ESTRO 2026
Digital Poster 4835 Elderly endometrial cancer patients: Are we doing well? Beatriz Gil Haro, Arancha Gallego Barranco, Irene Ávila Gómez, Jesús Romero Fernández, Francisco José González Rodríguez, María Moya Rodríguez, Raquel Benlloch Rodríguez, Marta López Valcárcel, María Hernández Miguel, Cristina De La Fuente Alonso, Sofía Santana Jiménez, Joaquín Velasco Jiménez, Irma Zapata Paz, María Isabel García Berrocal, Sofía Córdoba Largo Ratiation Oncology, Puerta de Hierro University Hospital, Madrid, Spain Purpose/Objective: To evaluate clinical outcomes, adverse events, and quality of life (QoL) in elderly patients receiving adjuvant radiotherapy—either intracavitary brachytherapy (IGBT) alone or combined with external beam radiotherapy (EBRT)—for endometrial cancer (EC). Material/Methods: Between December 2020 and December 2024, 39 elderly patients ( ≥ 70 years) with histologically confirmed EC were treated in our department. The mean age was 77 years (range, 70–91). All patients received EBRT, IGBT, or a combination of both, using 3D-based planning in accordance with GEC-ESTRO recommendations.For patients undergoing EBRT, the Skeletal Muscle Index (SMI) was measured from pre- treatment CT scans at the L3 vertebral level. Patients were classified into low (<39) and normal ( ≥ 39) SMI groups based on sex-specific cutoff values. Low SMI was considered sarcopenia. Body Mass Index (BMI)
Baseline fatigue scores were similar between patients treated with and without chemotherapy (29 vs. 31). At RadEnd, fatigue was higher among patients receiving chemotherapy compared with those receiving RT alone (62 vs. 52), but the difference diminished by 6 months (34 vs. 35) and remained stable thereafter (Figure 1).
Conclusion: Fatigue peaked at the end of treatment and largely resolved within two years, suggesting it is primarily an acute treatment-related effect. The addition of chemotherapy had a limited long-term impact on fatigue burden in patients with head and neck cancer. References: 1. Zer A, Pond GR, Razak ARA, Tirona K, Gan HK, Chen EX, et al. Association of neurocognitive deficits with radiotherapy or chemoradiotherapy for patients with head and neck cancer. JAMA otolaryngology–head & neck surgery. 2018;144(1):71-9.2. Klein J, Livergant J, Ringash J. Health related quality of life in head and neck cancer treated with radiation therapy with or without chemotherapy: a systematic review. Oral oncology. 2014;50(4):254-62.3. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5). Keywords: Fatigue, head and neck cancer, QOL
was also analyzed and categorized as <30 (normal/overweight) or ≥ 30 (obese). Patient characteristics are summarized in Figure 1.
Made with FlippingBook - Share PDF online